WeVote
Log In

Bill

Bill

A 4948

Prohibits pharmacy benefits managers from operating pharmacy practice sites directly or indirectly.

2026-2027 Regular Session

PBMs would be barred from owning, operating, or having any financial interest in any pharmacy practice site in New Jersey.

Introduced, Referred to Assembly Financial Institutions and Insurance Committee
0
WeVote Research Nonpartisan
Bill Summary · A 4948

Summary of New Jersey Assembly Bill A-4948 (Session 222)

Title

Prohibits pharmacy benefits managers from operating pharmacy practice sites directly or indirectly.

Purpose and Intent

The bill aims to prevent pharmacy benefit managers (PBMs) from owning or operating pharmacies or any related pharmacy practice sites. By restricting PBMs from direct or indirect control of physical pharmacies where prescriptions are filled, the measure seeks to address potential conflicts of interest, ensure greater transparency in pharmacy operations, and protect consumers from perceived steering or favoritism in the dispensing of medications.

Key Provisions and Changes

  • Prohibition on PBM Ownership/Control of Pharmacy Sites

    • PBMs would be barred from owning, operating, or having a financial interest in any pharmacy practice site (including retail and mail-order pharmacies) in New Jersey.
    • The prohibition applies to both direct ownership and indirect control (such as through affiliated entities or management arrangements).

  • Scope of “Pharmacy Practice Site”

    • Emphasizes physical locations where prescription medications are dispensed to patients, including retail pharmacies, supermarket or drugstore locations, and other dispensing sites under the PBM umbrella.

  • Civil and Administrative Remedies

    • Establishes enforcement mechanisms and potential penalties for violations.
    • May authorize the State Attorney General or appropriate regulatory bodies to investigate and issue sanctions, fines, or corrective actions.

  • Effective Date and Phased Implementation

    • The bill would specify an effective date or tiered timeline for compliance.
    • Potential transitional provisions for existing contracts or licenses, detailing how current arrangements must be divested or restructured.

  • Regulatory and Reporting Requirements

    • May require PBMs to provide information to the state regarding ownership structures, affiliations, and business arrangements.
    • Could mandate periodic reporting or audits to ensure compliance with the prohibition.

Who Would Be Affected

  • Pharmacy Benefits Managers (PBMs)

    • Primary entities affected; must restructure business models to remove any ownership or management role in dispensing sites.

  • Pharmacies and Pharmacists

    • Indirectly affected through changes in ownership and control relationships; may affect operations if PBM affiliations previously influenced dispensing practices.

  • Insurers and Prescription Benefit Plans

    • Plans administered by PBMs may be impacted due to changes in contract structures and network arrangements.

  • Consumers in New Jersey

    • Potentially benefit from reduced conflicts of interest and increased transparency in pharmacy dispensing and price-setting processes.

Procedural and Timeline Considerations

  • Legislative Process

    • As an Assembly bill, it would need passage by the New Jersey General Assembly and Senate, followed by the Governor’s signature or override of a veto.

  • Compliance Timeline

    • If enacted, the bill would include a specified effective date and any applicable grace periods, with staged deadlines for divestment or restructuring of current PBM-owned or controlled pharmacies.

  • Enforcement

    • Likely to establish state regulatory oversight and penalties for non-compliance, including possible fines, license suspensions, or other sanctions.

Potential Impacts and Implications

  • Market Structure

    • Could reduce vertical integration between PBMs and dispensing pharmacies, potentially increasing competition among pharmacies.

  • Consumer Protections

    • Addresses potential conflicts of interest that could influence drug dispensing, formulary decisions, or pricing practices.

  • Contractual Dynamics

    • May prompt renegotiation of PBM-pharmacy contracts and reallocation of profit streams tied to dispensing operations.

If you would like, I can tailor this summary to include specific section-by-section language once the bill text is available, or compare it to related bills (e.g., other states’ PBM ownership restrictions).

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.